H.C. Wainwright Maintains Pliant Therapeutics(PLRX.US) With Hold Rating
Pliant Therapeutics Analyst Ratings
Neutral Rating on Pliant Therapeutics Amid Early Promising Data and Uncertainties
H.C. Wainwright Maintains Pliant Therapeutics(PLRX.US) With Hold Rating
Pliant Therapeutics Is Maintained at Neutral by Citigroup
Pliant Therapeutics Price Target Cut to $1.50/Share From $4.00 by Citigroup
Pliant Therapeutics Is Maintained at Equal-Weight by Wells Fargo
CCORF Maintains Pliant Therapeutics(PLRX.US) With Hold Rating, Maintains Target Price $4
Oppenheimer Maintains Pliant Therapeutics(PLRX.US) With Hold Rating
Analysts Conflicted on These Healthcare Names: Pliant Therapeutics (PLRX) and Capricor Therapeutics (CAPR)
A Quick Look at Today's Ratings for Pliant Therapeutics(PLRX.US), With a Forecast Between $3 to $17
Pliant Therapeutics Price Target Maintained With a $10.00/Share by Needham
Pliant Therapeutics Cut to Hold From Buy by Needham
RBC Cuts Price Target on Pliant Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk
RBC Capital Reaffirms Their Hold Rating on Pliant Therapeutics (PLRX)
Hold Rating on Pliant Therapeutics Amidst BEACON-IPF Study Discontinuation and Uncertainty in Pipeline Prioritization
Pliant Therapeutics Analyst Ratings
Leerink Partners Downgrades Pliant Therapeutics to Market Perform, Lowers Price Target to $2
TD Cowen Maintains Pliant Therapeutics(PLRX.US) With Buy Rating
H.C. Wainwright Maintains Pliant Therapeutics(PLRX.US) With Hold Rating